Executive Summary Alzheimer’s disease (AD) has continued to evade researchers for over 100 years since its discovery, despite its substantial prevalence and recognition as an area of high unmet need The costs of caring for patients with AD are expected to exceed USD 20 trillion over the next 30 years,…
Executive Summary The 2019 NRDL update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed during the 2019 NRDL, the use of a new competitive…
This week CBPartners attended the heavily anticipated Virtual ISPOR 2020. A global conference that welcomes health professionals from around the world and this year hosted more than 1300 attendees from 54 countries. The event enables representatives from all areas of healthcare to come together to hear from experts and stakeholders…
Executive Summary Ongoing clinical trial disruptions due to COVID-19, such as: operational delays, enrollment challenges, protocol adjustments, and decreased short- / moderate-term persistence, contribute to the uncertain outlook for industry research programs Small-cap, clinical-stage biopharma companies lacking a cashflow from marketed products stand to be particularly affected by COVID-19. A…
Key takeaways: The COVID-19 outbreak puts healthcare systems at risk due to both acute operational impacts and broad financial disruptions, but the extent of the financial impact is still uncertain Similarly, austerity measures across the EU in response to the 2008 recession resulted in more restrictive healthcare budgets and pharmaceutical…
Executive Summary Tumor-agnostic treatments first came to market in 2017 with the revolutionary indication extension of KEYTRUDA® into microsatellite instability-high cancer Since then we have seen two more products launch: VITRAKVI® and ROZLYTREK®. While the products gained access in the USA market, the first tumor-agnostic product to be approved in Europe,…
Key takeaways: After focusing efforts on protein and more recently RNA targets, the bio-pharmaceutical industry is now getting ready to modify DNA, the final piece of the central dogma of molecular biology While genome editing technologies were being developed for many years, it is only now that we are…
As drug reimbursement continues to evolve with some areas converging. The global payer approach to decision making offers significant variation across geographies. Key takeaways Several factors contribute towards manufacturers seeking new ways to develop global drug pricing strategies Product launches vary based on geography; when comparing the USA to…
The American Society of Hematology’s (ASH) annual meeting is a well-established indicator of the innovations that are coming down the pipeline for hematologic diseases. As this year’s meeting approaches (Dec 7-10), CBPartners’ experts from our Cell and Gene Therapy Center of Excellence have selected 8 promising presentations on the future…
Executive Summary In 2011, The Cancer Drugs Fund (CDF) was launched to help patients in England access cancer drugs that had been rejected by the NHS As a result of financial struggles, the CDF faced a reform and partnered with NICE and pharmaceutical companies The partnership has led to earlier…